ArticlePediatrics2014
A multicenter cohort study of treatments and hospital outcomes in neonatal abstinence syndrome.
Article in Pediatrics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02851303 (Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome), which is not on this map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 129 citations in OpenAlex.
- Opioid treatment for opioid withdrawal in newborn infants.The Cochrane database of systematic reviews · 2021Pooled it
- Outcome reporting in neonates experiencing withdrawal following opioid exposure in pregnancy: a systematic review.Trials · 2020Pooled it
- Accelerated Weaning of Opioids to Reduce Pharmacologic Exposure for Neonatal Opioid Withdrawal Syndrome: A Randomized Clinical Trial.The Journal of pediatrics · 2026Trial
- Morphine versus methadone for neonatal opioid withdrawal syndrome: a randomized controlled pilot study.BMC pediatrics · 2022Trial
- Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome: A Pilot Study.The Journal of pediatrics · 2015Trial
- Neonatal opioid toxicity: opioid withdrawal (abstinence) syndrome with emphasis on pharmacogenomics and respiratory depression.Archives of toxicology · 2023Review
- A mini review of what matters in the management of NAS, is ESC the best care?Frontiers in pediatrics · 2023Review
- Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids.Journal of personalized medicine · 2022Review
- Variations and similarities in neonatal abstinence syndrome care and management across tertiary care hospitals in West Virginia.Journal of perinatology : official journal of the California Perinatal Association · 2022Article
- Hospital Outcomes of Infants with Neonatal Opioid Withdrawal Syndrome at a Tertiary Care Hospital with High Rates of Concurrent Nonopioid (Polysubstance) Exposure.American journal of perinatology · 2022Article
- Comparison of Two Morphine Dosing Strategies in the Management of Neonatal Abstinence Syndrome.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2022Article
- Multilevel factors associated with length of stay for neonatal abstinence syndrome in Florida's NICUs: 2010-2015.Journal of perinatology : official journal of the California Perinatal Association · 2021Article
- Project Console: a quality improvement initiative for neonatal abstinence syndrome in a children's hospital level IV neonatal intensive care unit.BMJ open quality · 2021Article
- Phenobarbital and Clonidine as Secondary Medications for Neonatal Opioid Withdrawal Syndrome.Pediatrics · 2021Article
- Physiologic Indirect Response Modeling to Describe Buprenorphine Pharmacodynamics in Newborns Treated for Neonatal Opioid Withdrawal Syndrome.Clinical pharmacokinetics · 2021Article
- Use of Phenobarbital to Treat Neonatal Abstinence Syndrome From Exposure to Single vs. Multiple Substances.Frontiers in pediatrics · 2021Article
- Site-Level Variation in the Characteristics and Care of Infants With Neonatal Opioid Withdrawal.Pediatrics · 2021Observational
- Subclinical and Overt Newborn Opioid Exposure: Prevalence and First-Year Healthcare Utilization.The Journal of pediatrics · 2020Article
- Association of a Simplified Finnegan Neonatal Abstinence Scoring Tool With the Need for Pharmacologic Treatment for Neonatal Abstinence Syndrome.JAMA network open · 2020Article
- Neonatal abstinence syndrome management in California birth hospitals: results of a statewide survey.Journal of perinatology : official journal of the California Perinatal Association · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 1 country.
Funding
Abstract
objectivesTo compare pharmacologic treatment strategies for neonatal abstinence syndrome (NAS) with respect to total duration of opioid treatment and length of inpatient hospital stay.
methodsWe conducted a cohort analysis of late preterm and term neonates who received inpatient pharmacologic treatment of NAS at one of 20 hospitals throughout 6 Ohio regions from January 2012 through July 2013. Physicians managed NAS using 1 of 6 regionally based strategies.
resultsAmong 547 pharmacologically treated infants, we documented 417 infants managed using an established NAS weaning protocol and 130 patients managed without protocol-driven weaning. Regardless of the treatment opioid chosen, when we accounted for hospital variation, infants receiving protocol-based weans experienced a significantly shorter duration of opioid treatment (17.7 vs. 32.1 days, P < .0001) and shorter hospital stay (22.7 vs. 32.1 days, P = .004). Among infants receiving protocol-based weaning, there was no difference in the duration of opioid treatment or length of stay when we compared those treated with morphine with those treated with methadone. Additionally, infants treated with phenobarbital were treated with the drug for a longer duration among those following a morphine-based compared with methadone-based weaning protocol. (P ≤ .002).
conclusionsUse of a stringent protocol to treat NAS, regardless of the initial opioid chosen, reduces the duration of opioid exposure and length of hospital stay. Because the major driver of cost is length of hospitalization, the implications for a reduction in cost of care for NAS management could be substantial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.